Pertussis
diseaseOn this page
Also known as Bordetella infectionBordetella pertussis caused disease or disorderBordetella pertussis disease or disorderBordetella pertussis infectionBordetella pertussis infectious diseasewhooping cough
Summary
Pertussis (MONDO:0005077) is a disease and 212 clinical trials. Top therapeutic interventions include hepatitis b virus hbsag surface protein antigen, montelukast, and diphtheria toxoid. A subtype of respiratory system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
- Clinical trials: 212
Clinical features
Epidemiology
Prevalence records
30 prevalence record(s), Orphanet, top 20 (validated / broadest geography first):
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 100 000 | 8.9 | Europe | Validated |
| Annual incidence | 1-9 / 100 000 | 9.76 | Austria | Validated |
| Annual incidence | 1-5 / 10 000 | 10.08 | Belgium | Validated |
| Annual incidence | 1-9 / 100 000 | 1.08 | Bulgaria | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.88 | Cyprus | Validated |
| Annual incidence | 1-5 / 10 000 | 10.7 | Czech Republic | Validated |
| Annual incidence | 1-5 / 10 000 | 19.16 | Denmark | Validated |
| Annual incidence | 1-9 / 100 000 | 4.66 | Estonia | Validated |
| Annual incidence | 1-9 / 100 000 | 5.1 | Finland | Validated |
| Annual incidence | 1-5 / 10 000 | 15.4 | Germany | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.38 | Greece | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.16 | Hungary | Validated |
| Annual incidence | 1-9 / 100 000 | 2.34 | Croatia | Validated |
| Annual incidence | 1-9 / 100 000 | 5.3 | Iceland | Validated |
| Annual incidence | 1-9 / 100 000 | 3.58 | Ireland | Validated |
| Annual incidence | 1-9 / 100 000 | 1.2 | Italy | Validated |
| Annual incidence | 1-9 / 100 000 | 8.48 | Latvia | Validated |
| Annual incidence | 1-9 / 100 000 | 2.22 | Lithuania | Validated |
| Annual incidence | 1-9 / 100 000 | 2.14 | Luxembourg | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.52 | Malta | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | pertussis |
| Mondo ID | MONDO:0005077 |
| EFO | EFO:0000650 |
| MeSH | D014917 |
| Orphanet | 1489 |
| DOID | DOID:1116 |
| NCIT | C85231 |
| SNOMED CT | 27836007 |
| UMLS | C0043167 |
| MedGen | 12159 |
| GARD | 0008692 |
| MedDRA | 10034738, 10047974 |
| NORD | 1569 |
| Is cancer (heuristic) | no |
Also known as: Bordetella infection · Bordetella pertussis caused disease or disorder · Bordetella pertussis disease or disorder · Bordetella pertussis infection · Bordetella pertussis infectious disease · pertussis · whooping cough
Disease family
This is a subtype of respiratory system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › respiratory system disorder › pertussis
Related subtypes (58): lower respiratory tract disorder, respiratory system cancer, respiratory system benign neoplasm, allergic respiratory disease, paranasal sinus disorder, upper respiratory tract disorder, severe acute respiratory syndrome, sleep apnea syndrome, diaphragm disorder, pulmonary tuberculosis, altitude sickness, perinatal asphyxia, pulmonary nodular lymphoid hyperplasia, tracheobronchopathia osteochondroplastica, Williams-Campbell syndrome, cystic fibrosis, growth delay-hydrocephaly-lung hypoplasia syndrome, laryngo-onycho-cutaneous syndrome, congenital pulmonary lymphangiectasia, familial primary pulmonary hypoplasia, Mounier-Kuhn syndrome, Young syndrome, lung agenesis-heart defect-thumb anomalies syndrome, sudden infant death-dysgenesis of the testes syndrome, alpha 1-antitrypsin deficiency, hereditary sclerosing poikiloderma with tendon and pulmonary involvement, autoimmune interstitial lung disease-arthritis syndrome, mucopolysaccharidosis-plus syndrome, congenital bronchobiliary fistula, bronchogenic cyst, primary ciliary dyskinesia, congenital pulmonary airway malformation, transient hyperammonemia of the newborn, congenital pulmonary sequestration, Siegler-Brewer-Carey syndrome, tracheal agenesis, 16q24.1 microdeletion syndrome, staphylococcal necrotizing pneumonia, pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis, plastic bronchitis, recurrent respiratory papillomatosis, IgG4-related mediastinitis, bronchopulmonary dysplasia, infantile apnea, diffuse alveolar hemorrhage, respiratory or thoracic malformation, pulmonary agenesis, eosinophilic granuloma, disorder of pharynx, respiratory tract neoplasm, pulmonary alveolar proteinosis with hypogammaglobulinemia, respiratory tract infectious disorder, Middle East respiratory syndrome, reactive airway disease, acinar dysplasia, pulmonary hypoplasia, isolated left bronchial isomerism, bronchiectasis and nasal polyposis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
6 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Bordetella Pertussis Filamentous Hemagglutinin | Approved (phase 4) |
| Bordetella Pertussis Pertactin Autotransporter | Approved (phase 4) |
| Bordetella Pertussis Toxin | Approved (phase 4) |
| Erythromycin | Approved (phase 4) |
| Erythromycin Ethylsuccinate | Approved (phase 4) |
| Hepatitis B Virus Hbsag Surface Protein Antigen | Approved (phase 4) |
| Human Immunoglobulin G | Phase 3 (in late-stage trials) |
| Pertussis Vaccine | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Azithromycin.
Clinical trials & evidence
Clinical trials
Clinical trials: 212.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 64 |
| Not specified | 63 |
| PHASE4 | 39 |
| PHASE2 | 18 |
| PHASE1 | 17 |
| PHASE1/PHASE2 | 5 |
| PHASE2/PHASE3 | 4 |
| EARLY_PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06803524 | PHASE4 | RECRUITING | 10-year Follow-up After a Single Dose Acellular Pertussis Vaccination |
| NCT00168545 | PHASE4 | COMPLETED | Immunology of Non-specific Effects of Vaccine |
| NCT00254917 | PHASE4 | COMPLETED | Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines |
| NCT00255021 | PHASE4 | COMPLETED | Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand |
| NCT00304265 | PHASE4 | COMPLETED | Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine |
| NCT00319553 | PHASE4 | COMPLETED | Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® |
| NCT00336115 | PHASE4 | UNKNOWN | The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients |
| NCT00347958 | PHASE4 | COMPLETED | Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine |
| NCT00457249 | PHASE4 | COMPLETED | A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older |
| NCT00514059 | PHASE4 | COMPLETED | Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine |
| NCT00617812 | PHASE4 | COMPLETED | Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine |
| NCT00674908 | PHASE4 | COMPLETED | Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine |
| NCT00712959 | PHASE4 | COMPLETED | Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose |
| NCT00777257 | PHASE4 | COMPLETED | Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine |
| NCT00802867 | PHASE4 | COMPLETED | Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ |
| NCT00870350 | PHASE4 | UNKNOWN | An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster |
| NCT00877357 | PHASE4 | UNKNOWN | Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine |
| NCT01031303 | PHASE4 | COMPLETED | Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age |
| NCT01137435 | PHASE4 | COMPLETED | Post Marketing Surveillance for ADACEL™ in South Korea |
| NCT01279668 | PHASE4 | UNKNOWN | Montelukast for Persistent Cough in Young People and Adults |
| NCT01311557 | PHASE4 | COMPLETED | Study of Adacel® Vaccine Administered to Persons 10 Years of Age |
| NCT01357720 | PHASE4 | COMPLETED | Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination |
| NCT01437423 | PHASE4 | COMPLETED | Regulatory Post-Marketing Surveillance Study for TETRAXIM™ |
| NCT01439165 | PHASE4 | COMPLETED | Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose |
| NCT01491087 | PHASE4 | COMPLETED | Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China |
| NCT01629589 | PHASE4 | COMPLETED | Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents |
| NCT01659996 | PHASE4 | COMPLETED | Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age |
| NCT01698346 | PHASE4 | COMPLETED | Pertussis (Tdap) Vaccination in Pregnancy |
| NCT01711645 | PHASE4 | COMPLETED | Tdap Vaccine in Post-Partum Women |
| NCT02408926 | PHASE4 | COMPLETED | Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand |
| NCT02526394 | PHASE4 | COMPLETED | Pertussis and Meningitis C Concomitant Vaccination in Adolescents |
| NCT02771782 | PHASE4 | UNKNOWN | Influence of BCG on TDaP-IPV Vaccination |
| NCT03606096 | PHASE4 | UNKNOWN | Gambia Pertussis Study (GaPs) |
| NCT03697798 | PHASE4 | COMPLETED | A Study Exploring Whooping Cough Protection in Children and Adults |
| NCT03908164 | PHASE4 | UNKNOWN | Optimising the Timing of Whooping Cough Immunisation in MUMs |
| NCT03909126 | PHASE4 | COMPLETED | Pertussis Vaccination in Pregnant Women |
| NCT04056728 | PHASE4 | UNKNOWN | A Phase IV Study to Assess the Safety of EupentaTM Inj |
| NCT04543669 | PHASE4 | COMPLETED | Adacel® Booster Vaccination for CMI Assay Development |
| NCT05856396 | PHASE4 | COMPLETED | Maternal Determinants of Infant Immunity to Pertussis |
| NCT05091619 | PHASE3 | ACTIVE_NOT_RECRUITING | A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN | 4 | 3 |
| MONTELUKAST | 4 | 3 |
| DIPHTHERIA TOXOID | 4 | 1 |
| PENTETIC ACID | 4 | 1 |
| ROTAVIRUS, LIVE ATTENUATED | 4 | 1 |
| STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 | 4 | 1 |
| TECHNETIUM TC 99M PENTETATE | 4 | 1 |
| TETANUS TOXOID | 4 | 1 |
| PERTUSSIS VACCINE | 3 | 4 |
| LUFENURON | 2 | 1 |
| CHEMBL5205127 | 0 | 1 |